“…54 SBCE improves the detection of lesions in the proximal small bowel when compared to both CTE and MRE, detecting proximal lesions in up to 50% of patients with previously diagnosed ileal CD. 55 Jejunal involvement has been recognized as an independent marker of severity in CD, being associated with an increased risk of relapse, 55 higher use of corticosteroids (HR 1.24; 95% CI: 1.02 -1.50) and thiopurines (HR 1.26; 95% CI: 1.06 -1.49), higher rates of strictureplasties (RR 2.52; 95% CI: 1.60 -3.96), hospitalizations (RR 1.29; 95% CI: 1.14 -1.47), and longer hospitalization duration (RR, 1.30; 95% CI, 1.25 -1.34). 56 Recently, it was reported that treatment with thiopurines and/or biologics was started more often in patients with proximal small bowel lesions detected by SBCE [13/33 (39%) vs 1/17 (6%), p = 0.011, relative risk (RR) 6.5], particularly when severe (6%, 36% and 45% of patients with non-significant, mild and moderate-to-severe inflammation, respectively).…”